Clinical trial
Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating…
NCT00454194 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00454194 |
|---|---|
| Title | Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
| Official title | Phase II Randomized Study of Pemetrexed With Sorafenib Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | pemetrexed disodium, sorafenib tosylate |
| Enrollment | 110 |
| Start date | Sep 1, 2007 |
| Primary completion | Jul 1, 2010 |
| Completion | May 1, 2013 |
| First posted | Mar 30, 2007 |
| Last update posted | Mar 21, 2017 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: